Topics

Study to Collect Information About Serious Infections Caused by E.Coli Bacteria

2019-06-04 23:11:26 | BioPortfolio

Summary

The purpose of this study is to collect information from study participants who develop a serious infection caused by a bacterium called E.coli during a period of 12 months. This information will be used to support the development of a new vaccine to prevent E.coli infections.

Description

Invasive ExPEC disease (IED) is defined as an acute illness consistent with bacterial infection that is microbiologically confirmed by the isolation and identification of E. coli from blood or other normally sterile body sites, or by the isolation and identification of E. coli from urine in a patient with signs and symptoms of invasive disease and no other identifiable source of infection. Adults aged 60 years or older have an increased risk of developing IED. To date, there is no vaccine available to prevent IED. ExPEC10V is a 10 valent vaccine candidate in development by Janssen R&D for the prevention of IED in adults aged 60 years and older. A Phase 3 clinical study is planned to investigate the efficacy and safety of this vaccine. To obtain insight in the feasibility and design of the Phase 3 study, a pilot study is required.

This pilot study is a prospective, multicenter, observational study conducted in a maximum of eight countries in Europe, North-America and Asia. Participant recruitment will be done in primary care. In each participating country a local primary care network encompassing approximately 40,000 persons and a local hospital, where patients are referred to in case of a suspicion of IED, will participate in this study.

Database screening at the primary care centers will be performed to identify and invite potential eligible study participants. Upon consent, each study participant will be followed for a period of maximum 12 months after enrollment in the study. At baseline, demographic data and medical history data will be collected. During the follow-up period, any referral of study participants to a hospital for any reason including IED will be collected. IED identification and Medical Resource Utilization (MRU) during the follow-up period will be done by performing regular telephone calls with all study participants. At the end of the study, the primary care files will also be checked for MRU. If a participant is diagnosed with IED and admitted to the hospital, the following data will be collected: medical history and treatment received 90 days prior to the IED, clinical and laboratory data, data on the treatment and outcome of IED and data on MRU related to IED. Data will be collected on Day 1 of IED diagnosis (signs/symptoms) and Day 28 after IED diagnosis. In addition, E. coli bacteria cultured from blood, urine or other normally sterile body sites/fluid will be isolated. Representative bacterial colonies will be identified to the species level as per local laboratory procedures.

Study Design

Conditions

E.Coli Infections

Status

Not yet recruiting

Source

UMC Utrecht

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-06-04T23:11:26-0400

Clinical Trials [427 Associated Clinical Trials listed on BioPortfolio]

Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol

The purpose of this study is to review patients with E. coli infections at UPMC from September 1, 2008 to August 31, 2010 to determine if these infections have arisen in the community rath...

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This informa...

Antibiotic Resistant Community-Acquired E. Coli

The purpose of this study is to review patients with E. coli infections at UPMC from January 1, 2004 to December 31, 2005 to determine if these infections have arisen in the community rath...

Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli

The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from July 1, 2007 to June 30, 2010 to determine if these infec...

Quinolone Resistance in Bloodstream Isolates of Escherichia Coli

This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloo...

PubMed Articles [4888 Associated PubMed Articles listed on BioPortfolio]

Identifying geographic origins of the Escherichia coli isolates from food by a method based on single-nucleotide polymorphisms.

E.coli is an important foodborne pathogen. Rapid and robust tracking of the source of E. coli is the key step to control foodborne infections.

Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey.

Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of patients with haematological malignancies (HM) and Escherichia coli represent one of the most frequent cau...

A ten-year review of ESBL and non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral hospital in South Africa.

There are few studies describing Escherichia coli (E. coli) bloodstream infection (BSI) among children in Africa, yet E.coli is increasing in importance as a cause of antibiotic resistant infection in...

Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales after rectal colonisation with ESBL-producing Escherichia coli or Klebsiella pneumoniae.

Infections due to extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) are considered infections with a high public health burden. In this study, we aimed to identify incidences of and...

Molecular epidemiology and nitrofurantoin resistance determinants from nitrofurantoin non-susceptible Escherichia coli isolated from urinary tract infections.

The worldwide emergence of multidrug resistant uropathogens has resulted in revival of old antibiotics, like nitrofurantoin (NIT) for treatment of uncomplicated urinary tract infections. We aimed to i...

Medical and Biotech [MESH] Definitions

Infections with bacteria of the species ESCHERICHIA COLI.

Strains of Escherichia coli that possess virulence traits which allow them to invade, colonize, and induce disease in tissues outside of the GASTROINTESTINAL TRACT. They are a cause of URINARY TRACT INFECTIONS (UROPATHOGENIC ESCHERICHIA COLI); neonatal MENINGITIS; SEPSIS; PNEUMONIA; and SURGICAL WOUND INFECTION.

Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.

Strains of Escherichia coli that preferentially grow and persist within the urinary tract. They exhibit certain virulence factors and strategies that cause urinary tract infections.

Strains of ESCHERICHIA COLI that are a subgroup of SHIGA-TOXIGENIC ESCHERICHIA COLI. They cause non-bloody and bloody DIARRHEA; HEMOLYTIC UREMIC SYNDROME; and hemorrhagic COLITIS. An important member of this subgroup is ESCHERICHIA COLI O157-H7.

More From BioPortfolio on "Study to Collect Information About Serious Infections Caused by E.Coli Bacteria"

Quick Search

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Searches Linking to this Trial